TY - JOUR
T1 - Rational Design Principles of Attenuated Cationic Lytic Peptides for Intracellular Delivery of Biomacromolecules
AU - Tamemoto, Naoki
AU - Tamemoto, Naoki
AU - Akishiba, Misao
AU - Sakamoto, Kentarou
AU - Kawano, Kenichi
AU - Noguchi, Hiroshi
AU - Futaki, Shiroh
N1 - Funding Information:
This work was supported by JST CREST (grant number JPMJCR18H5) and JSPS KAKENHI (grant numbers 18H04403 and 18H04017). M.A. and K.S. are grateful for the JSPS Research Fellowship for Young Scientists. The computational simulations in this work were carried out using the facilities of the Supercomputer Center, the Institute for Solid State Physics, the University of Tokyo.
Publisher Copyright:
© 2020 American Chemical Society.
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Intracellular delivery of bioactive macromolecules via endocytic pathways has utility in biotechnological and medicinal applications. Various endosomolytic peptides bearing glutamic acid (Glu) residues have been developed with the aim to achieve selective lysis of endosomal membranes without damaging cell membranes (plasma membranes) to release endosome-entrapped macromolecules and obtain their bioactivity. Glu residues on peptides are negatively charged in the extracellular medium, and substitution of this residue onto membrane-lytic peptides prevents its peptide-membrane interaction and its lytic activity. On the other hand, within endosomes, which have a reduced pH of ∼5, Glu is protonated, resulting in the reduction of the hydrophilicity of the peptide, unmasking its lytic activity. Despite this, a limited number of studies have elucidated the optimum positions for Glu substitution. This report investigated the positioning of Glu and the endosomolytic activities of cationic lytic peptides, ponericin-W3, and melittin. By cell-based assays, biophysical analyses, and molecular dynamics simulations, we found that analogues with Glu positioned on the borders between the hydrophobic and hydrophilic faces of the helical structures showed better performance than placing Glu within said faces.
AB - Intracellular delivery of bioactive macromolecules via endocytic pathways has utility in biotechnological and medicinal applications. Various endosomolytic peptides bearing glutamic acid (Glu) residues have been developed with the aim to achieve selective lysis of endosomal membranes without damaging cell membranes (plasma membranes) to release endosome-entrapped macromolecules and obtain their bioactivity. Glu residues on peptides are negatively charged in the extracellular medium, and substitution of this residue onto membrane-lytic peptides prevents its peptide-membrane interaction and its lytic activity. On the other hand, within endosomes, which have a reduced pH of ∼5, Glu is protonated, resulting in the reduction of the hydrophilicity of the peptide, unmasking its lytic activity. Despite this, a limited number of studies have elucidated the optimum positions for Glu substitution. This report investigated the positioning of Glu and the endosomolytic activities of cationic lytic peptides, ponericin-W3, and melittin. By cell-based assays, biophysical analyses, and molecular dynamics simulations, we found that analogues with Glu positioned on the borders between the hydrophobic and hydrophilic faces of the helical structures showed better performance than placing Glu within said faces.
UR - http://www.scopus.com/inward/record.url?scp=85085714980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085714980&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.0c00312
DO - 10.1021/acs.molpharmaceut.0c00312
M3 - Article
C2 - 32352304
AN - SCOPUS:85085714980
SN - 1543-8384
VL - 17
SP - 2175
EP - 2185
JO - Molecular pharmaceutics
JF - Molecular pharmaceutics
IS - 6
ER -